Evidence map›Paper›PMID 25548801›Full record

ReviewCellular and molecular life sciences : CMLS2015

Metabolic effects of resveratrol: addressing the controversies.

Jacob L Bitterman, Jay H Chung

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. 3,4',5-Trimethoxy-Antioxidants (Basel, Switzerland) · 2022
    Article
  18. Review
  19. Review
  20. Obesity and Male Reproduction: Do Sirtuins Play a Role?International journal of molecular sciences · 2022
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jacob L BittermanLaboratory of Obesity and Aging Research, Genetics and Developmental Biology Center, National Heart Lung and Blood Institute, National Institutes of Health, 10 Center Drive Building 10 Room 7D14, Bethesda, MD, 20892, USA, jacob.bitterman@nih.gov.
Jay H Chung

Funding

Treatment for obesityZIAHL006118 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHUNG, JAY H · 2011 to 2019
$11.2M
The role of energy in stress signalingZ01HL002243 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHUNG, JAY H · 1999 to 2008
$4.6M
Intramural NIH HHS Z01 HL002243
6 · The paper itself

Abstract

Resveratrol, a polyphenol found in a number of plant-based foods such as red wine, has received a great deal of attention for its diverse array of healthful effects. Beneficial effects of resveratrol are diverse; they include improvement of mitochondrial function, protection against obesity and obesity-related diseases such as type-2 diabetes, suppression of inflammation and cancer cell growth and protection against cardiovascular dysfunction, just to name a few. Investigations into the metabolic effects of resveratrol are furthest along and now include a number of clinical trials, which have yielded mixed results. There are a number of controversies surrounding resveratrol that have not been resolved. Here, we will review these controversies with particular emphasis on its mechanism of metabolic action and how lessons from resveratrol may help develop therapies that harness the effects of resveratrol but without the undesirable properties of resveratrol.

Indexed as

AMP-Activated Protein KinasesAnimalsAntioxidantsCyclic Nucleotide Phosphodiesterases, Type 4Diabetes Mellitus, Type 2HumansLongevityNeuroprotective AgentsObesityResveratrolSignal TransductionSirtuin 1StilbenesAMP-Activated Protein KinasesAntioxidantsCyclic Nucleotide Phosphodiesterases, Type 4Neuroprotective AgentsResveratrolSirtuin 1Stilbenes

Identifiers

PMID25548801
PMCPMC6324849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.